Unoprostone

Drug Profile

Unoprostone

Alternative Names: Isopropyl unoprostone; Ocuseva; Rescula; UF-021; Unoprostone isopropyl

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator R-Tech Ueno Ltd
  • Developer R-Tech Ueno Ltd; Santen Pharmaceutical; Sucampo Pharmaceuticals
  • Class Antiglaucomas; Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide stimulants; Potassium channel agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Retinitis pigmentosa
  • Preclinical Age-related macular degeneration

Most Recent Events

  • 04 Jan 2017 Launched for Ocular hypertension in Japan (Topical)
  • 04 Jan 2017 Registered for Ocular hypertension in Japan (Topical) before January 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in Japan (Ophthalmic, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top